Kestra Medical Technologies (KMTS) Stock Jumps On Margin Gains Despite Deeper Losses

Kestra Medical Technologies came into this print with a mixed scorecard. The stock had fallen about 10% over the past month, even though the 90 day return was strongly positive. Then Q1 hit and the market snapped back, with the share price climbing 4.7% today.

What moved traders was not the loss. It was the combination of about $31.0 million in quarterly revenue and gross margin reaching 56.5%. For a medtech growth story that is still burning cash, that margin trajectory is the headline from this earnings release.

Love the 56.5% gross margin at Kestra Medical Technologies but worried about a cash burning growth story tied to a single ticker? Take a look at our list of solid balance sheet and fundamentals stocks (23 results)

Q1 2027 Kestra Medical Technologies Earnings Summary

• Revenue (Q1 2027 vs. Q1 2026): US$30.97m vs. US$19.37m (strong top line increase year over year)
• Net Loss (Q1 2027 vs. Q1 2026): loss of US$44.09m vs. loss of US$25.83m (deeper quarterly loss year over year)
• Basic EPS (Q1 2027 vs. Q1 2026): loss of US$0.75 per share vs. loss of US$0.50 per share (per share loss widened year over year)
• Gross Margin (Q1 2027 vs. Q1 2026): 56.5% vs. mid 40s percent range implied by management commentary (material margin improvement alongside continued cash burn)

Prefer clean charts over another wall of earnings figures and margin tables? Explore Kestra Medical Technologies through a full visual breakdown of its valuation picture in the company report for Kestra Medical Technologies.

Kestra Medical’s Bull Story Meets Real Operating Proof

Bulls argue Kestra Medical Technologies can scale ASSURE as a cardio recovery platform, lift payer quality and let margins do the heavy lifting while cash burn narrows over time. Q1 provides real evidence on those milestones. The top line reached about US$31.0m with 60% year on year growth, which aligns with the thesis that more clinicians are prescribing and more patients are converting to active rentals. Gross margin at 56.5% now sits more than 10 points above last year, consistent with the argument that better revenue management and scale were needed.

Management also reported in network mix in the low 80s% range compared with roughly 70% at the IPO. That is direct evidence the payer access story is progressing, which feeds into both revenue per fit and collections. The raised full year revenue outlook to US$141m indicates that these are not one off wins.

Compare Kestra Medical Technologies’ margin story and fit ramp with Wall Street’s reaction, then see whether analysts think this NasdaqGS:KMTS reset still has room to run in the consensus price target analysis for Kestra Medical Technologies.

Bear Concerns On Cash Burn And Execution Linger

The core worry around Kestra Medical Technologies is simple. Bears see a fast growing cardio device rental model that keeps spending heavily, struggles to convert coverage wins into profits, and risks needing more capital before the story matures.

Q1 does not fully disprove that. Revenue reached US$31.0m and gross margin hit 56.5%, yet the business still reported a GAAP net loss of US$44.1m and an Adjusted EBITDA loss of US$24m. Operating cash use of US$32.3m, even if seasonally elevated, supports the fear that cash burn remains sizable.

Execution risk also shows up in expenses. GAAP OpEx of US$55.2m, with FY2027 OpEx guided to about US$220m, means the commercial and R&D engine is still running well ahead of current income. Bears who argue that operating leverage is more aspiration than reality just picked up fresh ammunition.

Expose whether Kestra Medical Technologies’ heavy cash use, widening losses and shareholder dilution are early warnings or part of a deeper issue. Review the full risk analysis for Kestra Medical Technologies which shows 3 important warning signs.

Own Your Next Investing Move

If the mix of strong gross margin and heavy cash use at Kestra Medical Technologies caught your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a cleaner entry point. Once you are in the position, keep your decisions sharp by using the Portfolio Command Center to cut through noise and focus on the key developments that matter to your holdings. For long term context, lean on the Community to see how other investors are interpreting the same numbers and risks. That way you surface potential catalysts or warning signs early and give yourself a clearer view of changing conditions in the market.

Seeking Alternatives Beyond Kestra Medical Technologies?

Fresh ideas move first. While attention clusters around a few headlines, quieter stories can build breakout momentum under the radar for now. Scan these shortlists before the window drops and act now.

• Spot potential turnaround opportunities early by reviewing curated 11 resilient stocks with low risk scores that keep volatility in check while still offering room for upside moves.
• Chase accelerating earnings trends by scanning 75 profitable AI stocks that aren't just burning cash where cash flows already back the AI narrative instead of relying on distant promises.
• Track critical infrastructure plays by assessing 38 power grid technology and infrastructure stocks positioned to benefit if grid technology spending gains momentum while it still flies below most investors’ radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com